Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent

Clinical translation of long-acting drug delivery formulations

(2022) Wei Li et al.   Nature Reviews Materials

Challenges and opportunities in the development of complex generic long-acting injectable drug products

(2021) Matthew N. O'Brien et al.   JOURNAL OF CONTROLLED RELEASE

Lenacapavir: a first-in-class HIV-1 capsid inhibitor

(2021) Hadas Dvory-Sobol et al.   Current Opinion in HIV and AIDS

Clinical targeting of HIV capsid protein with a long-acting small molecule

(2020) John O. Link et al.   NATURE

539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans

(2018) Jim Zheng et al.   Open Forum Infectious Diseases

Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy

(2016) Andrew Owen et al.   ADVANCED DRUG DELIVERY REVIEWS

Formulation and pharmacology of long-acting cabotegravir

(2015) Christine Trezza et al.   Current Opinion in HIV and AIDS

Making the Leap from Daily Oral Dosing to Long-Acting Injectables: Lessons from the Antipsychotics

(2014) Julius F. Remenar   MOLECULAR PHARMACEUTICS